Activated CIK with CD3-MUC1
Cell therapyexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 25, 2018 (NCT03484962)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1Immunity, passive
MUC1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03509298 | Phase 2 | Apr 12, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
| NCT03540199 | Phase 2 | Apr 10, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
| NCT03524261 | Phase 2 | Apr 5, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
| NCT03524274 | Phase 2 | Apr 5, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
| NCT03501056 | Phase 2 | Mar 27, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
| NCT03484962 | Phase 2 | Mar 25, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. | For profit | 6 | 0 | 1 | 2018 |
| Guangzhou University | Academic/Hospital | 6 | 0 | 1 | 2018 |
| Jinan University | Academic/Hospital | 6 | 6 | 1 | 2018 |
3 organizations
Page 1 / 1